Skip to Main Content

Advertisement

Skip Nav Destination

Abstract CT102: APACHE: An open label, randomized, phase II study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage

Cancer Res (2018) 78 (13_Supplement): CT102.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Bi-Cheng Wang
  • Peng-Cheng Li
  • Ji-Quan Fan
  • Guo-He Lin
  • Quentin Liu
Medicine (2020) 99 (28): e21273.
Close Modal

or Create an Account

Close Modal
Close Modal